Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 6/20 | 0.68 |
| ▸ | PTGS1 | P23219 | 6/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.58 |
| ▸ | FAAH | O00519 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | XBP1 | P17861 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10079339 | 0.98 | MGLL (0.71) | MGLLPTGS1PTGS2FAAHALDH1A1 | |
| SCHEMBL13733359 | 0.98 | MGLL (0.71) | MGLLPTGS1PTGS2FAAHALDH1A1 | |
| SCHEMBL27420754 | 0.98 | MGLL (0.71) | MGLLPTGS1PTGS2FAAHALDH1A1 | |
| SCHEMBL16933147 | 0.98 | MGLL (0.71) | MGLLPTGS1PTGS2FAAHALDH1A1 | |
| SCHEMBL22311909 | 0.98 | MGLL (0.71) | MGLLPTGS1PTGS2FAAHALDH1A1 | |
| SCHEMBL15215618 | 0.98 | MGLL (0.71) | MGLLPTGS1PTGS2FAAHALDH1A1 | |
| SCHEMBL17732171 | 0.98 | MGLL (0.71) | MGLLPTGS1PTGS2FAAHALDH1A1 | |
| SCHEMBL5208692 | 0.98 | MGLL (0.71) | MGLLPTGS1PTGS2FAAHALDH1A1 | |
| SCHEMBL26422757 | 0.89 | PTGS1 (0.64) | MGLLPTGS1PTGS2FAAHALDH1A1 | |
| SCHEMBL10126653 | 0.88 | MGLL (0.67) | MGLLPTGS1PTGS2FAAHALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3972649-B1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS AG (CH) | 2026-05-13 | — | — | EP | disclosed |
| WO-2026042013-A1 | MITOCHONDRIAL THERAPY | INSTITUTE OF MOLECULAR AND CLINICAL OPHTHALMOLOGY BASEL (IOB) (CH) | 2026-02-26 | — | — | WO | disclosed |
| US-20260027220-A1 | EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2026-01-29 | — | — | US | disclosed |
| US-20250339547-A1 | MET BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2025-11-06 | — | — | US | disclosed |
| US-20250114441-A1 | POLYMERIC VACCINE FOR OPIOID ADDICTION | THE JOHNS HOPKINS UNVERSITY | 2025-04-10 | — | — | US | disclosed |
| EP-4525925-A1 | EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | Novartis AG (CH) | 2025-03-26 | — | — | EP | disclosed |
| EP-4525926-A1 | MET BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | Novartis AG (CH) | 2025-03-26 | — | — | EP | disclosed |
| US-20250064964-A1 | ANTIBODY DRUG CONJUGATES FOR ABLATING HEMATOPOIETIC STEM CELLS | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC. DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION (GNF) | 2025-02-27 | — | — | US | disclosed |
| US-12171839-B2 | Antibody drug conjugates for ablating hematopoietic stem cells | NOVARTIS AG (CH) | 2024-12-24 | — | — | US | disclosed |
| CN-113416229-B | Cytotoxic and antimitotic compounds and methods of use thereof | 酵活英属哥伦比亚有限公司 | 2024-12-13 | — | — | CN | disclosed |
| US-9498540-B2 | Cell proliferation inhibitors and conjugates thereof | NOVARTIS AG (CH) | 2016-11-22 | — | — | US | disclosed |
| US-20160311853-A1 | CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2016-10-27 | — | — | US | disclosed |
| EP-3082877-A2 | CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF | Novartis AG (CH) | 2016-10-26 | — | — | EP | disclosed |
| WO-2016146638-A1 | CRYPTOPHYCIN-BASED ANTIBODY-DRUG CONJUGATES WITH NOVEL SELF-IMMOLATIVE LINKERS | EXIRIS S.R.L. (IT) | 2016-09-22 | — | — | WO | disclosed |
| WO-2015095301-A2 | CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF | IRM LLC (BM) | 2015-06-25 | — | — | WO | disclosed |
| US-20140363454-A1 | Antibody-Drug Conjugates, Compositions and Methods of Use | IGENICA BIOTHERAPEUTICS, INC. (US) | 2014-12-11 | — | — | US | disclosed |
| US-20140322247-A1 | CELL PROLIFERATION INHIBITORS AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2014-10-30 | — | — | US | disclosed |
| US-20140322247-A1 | CELL PROLIFERATION INHIBITORS AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2014-10-30 | — | — | US | disclosed |
| US-7141691-B2 | Protein-bound derivatives of platinum complexes containing cyclobutane1, 1-dicarboxyllate ligands | KTB TUMORFORSCHUNGS GMBH (DE) | 2006-11-28 | — | — | US | disclosed |
| US-20060089341-A1 | Protein-bound derivatives of platinum complexes containing cyclobutane1,1-dicarboxyllate ligands | KTB TUMORFORSCHUNGS GMBH (DE) | 2006-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140363454-A1 | Antibody-Drug Conjugates, Compositions and Methods of Use | SDCBP, CD81, DSTN | MGLL 4637/4885PTGS1 4168/4885PTGS2 4318/4885 |
| US-20250064964-A1 | ANTIBODY DRUG CONJUGATES FOR ABLATING HEMATOPOIETIC STEM CELLS | ABL1, BCR, CD47 | MGLL 4860/4885PTGS1 4483/4885PTGS2 4716/4885 |
| US-20260027220-A1 | EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | EPHA2, EPHA1, EPHB1 | MGLL 4373/4885PTGS1 2769/4885PTGS2 3742/4885 |
| US-20250339547-A1 | MET BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | MET, BCL3, BCL9 | MGLL 2079/4885PTGS1 4446/4885PTGS2 4372/4885 |
| US-20060089341-A1 | Protein-bound derivatives of platinum complexes containing cyclobutane1,1-dicarboxyllate ligands | DDB1, DCLRE1A, PDCD1LG2 | MGLL 4755/4885PTGS1 2109/4885PTGS2 3364/4885 |
| US-20160311853-A1 | CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF | CD47, NGLY1, VIP | MGLL 4602/4885PTGS1 4232/4885PTGS2 4661/4885 |
| US-20250114441-A1 | POLYMERIC VACCINE FOR OPIOID ADDICTION | OPRM1, OPRK1, OPRL1 | MGLL 1411/4885PTGS1 2273/4885PTGS2 2124/4885 |
| US-20140322247-A1 | CELL PROLIFERATION INHIBITORS AND CONJUGATES THEREOF | MKI67, CCNI, PA2G4 | MGLL 4070/4885PTGS1 3295/4885PTGS2 3774/4885 |
| US-12171839-B2 | Antibody drug conjugates for ablating hematopoietic stem cells | BCR, ABL1, CD47 | MGLL 4849/4885PTGS1 4685/4885PTGS2 4781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.